

Proof of your article (# H-00617-2008) from "American Journal of Physiology-Heart and Circulatory Physiology" is available for download

=====

Dear Sir or Madam:

Please refer to this URL address

<http://rapidproof.cadmus.com/RapidProof/retrieval/index.jsp>

Login: your e-mail address

Password: ----

The file at the above URL address contains the following:

- Proofreading marks
- Reprint Order form
- Copyedited page proof of your article

The site contains 1 file. You will need Adobe Acrobat® Reader to read this file. Adobe Acrobat® Reader is a free software, available for user downloading at <http://www.adobe.com/products/acrobat/readstep.html>.

After you print the PDF file of your paper, please read the page proof carefully and

- 1) clearly indicate all changes or corrections on the margin;
- 2) answer all queries (footnotes 1, 2, 3, etc.) listed on the last page of the PDF proof;
- 3) carefully proofread all/any tables and equations;
- 4) make sure that any special characters, such as Greek letters, especially μ (mu), have translated correctly;
- 5) If you have questions about figure quality, note your concerns on the margin of the relevant page. Please keep in mind that the final printed version will be of higher quality than the PDF proof and that the online version of the published article will appear identical.

We encourage you to retain a copy of the proof with your corrections, should further changes and/or clarifications be required.

IMPORTANT NOTES

1. To guarantee the placement of your article in the next available issue of the "American Journal of Physiology-Heart and Circulatory Physiology", please return the corrected set of PDF page proof via an overnight courier service to this address WITHIN 48 HOURS:

The American Physiological Society

"American Journal of Physiology-Heart and Circulatory Physiology" PROOF

9650 Rockville Pike

Bethesda, MD 20814-3991

USA

phone: 301-634-7070

2. If you require a hard copy of your color image(s), you may request it by replying to this message. The color proof will then be provided to you at an additional fee of \$75.00 per color figure, which will be added to the publication fees for your article. You must provide the appropriate figure number(s) and your mailing address in your reply if you wish to receive the hard copy of the color proof(s).

3) The filled out Reprint Form must be returned within 24 hours to the address below:

Cadmus Professional Communications

Cadmus Reprints

PO Box 751903

Charlotte NC 28275-1903

USA

For reprint inquiries, please contact Mary Leonard, fax: 410-770-4659, e-mail: leonardm@cadmus.com.

If you have any problems or questions, please contact me.

PLEASE ALWAYS INCLUDE YOUR ARTICLE NO. (H-00617-2008) WITH ALL
CORRESPONDENCE.

Sincerely,

Joseph Girouard
Journal Editorial Supervisor
AJP-Heart and Circulatory Physiology

9650 Rockville Pike
Bethesda, Maryland 20814-3991 (USA)
Phone: 301-634-7223
Fax: 301-634-7243
E-mail: jgirouard@the-aps.org

Proofreader's Marks

MARK	EXPLANATION	EXAMPLE
	TAKE OUT CHARACTER INDICATED	Your proof.
^	LEFT OUT, INSERT	u Yor proof. ^
#	INSERT SPACE	# Yourproof. ^
9	TURN INVERTED LETTER	Your p ^l oof. ^
X	BROKEN LETTER	X Your pr ^o /of.
eg#	EVEN SPACE	eg# A good proof.
⊖	CLOSE UP: NO SPACE	Your pro ^o gf.
tr	TRANSPOSE	tr A proof good
wf	WRONG FONT	wf Your proof.
lc	LOWER CASE	lc Your proof.
≡ caps	CAPITALS	Your proof. caps Your proof.
ital	ITALIC	Your proof. ital Your proof.
rom	ROMAN, NON ITALIC	rom Your proof.
bf	BOLD FACE	Your proof. bf Your proof.
..... stet	LET IT STAND	Your proof. stet Your proof.
out sc.	DELETE, SEE COPY	out sc. She Our proof. ^
spell out	SPELL OUT	spell out Queen (Eliz.)
#	START PARAGRAPH	# read. [Your
no #	NO PARAGRAPH: RUN IN	no # marked. → # Your proof.
└	LOWER	└ [Your proof.]

MARK	EXPLANATION	EXAMPLE
┌	RAISE	┌ Your proof.
┐	MOVE LEFT	┐ Your proof.
└	MOVE RIGHT	└ Your proof.
	ALIGN TYPE	┐ Three dogs. Two horses.
≡	STRAIGHTEN LINE	≡ Your proof.
⊙	INSERT PERIOD	⊙ Your proof. ^
;/	INSERT COMMA	;/ Your proof. ^
:/	INSERT COLON	:/ Your proof. ^
;/	INSERT SEMICOLON	;/ Your proof. ^
∨	INSERT APOSTROPHE	∨ Your mans proof. ^
∨ ∨	INSERT QUOTATION MARKS	∨ ∨ Marked it proof. ^ ^
=/	INSERT HYPHEN	=/ A proofmark. ^
!	INSERT EXCLAMATION MARK	! Prove it. ^
?	INSERT QUESTION MARK	? Is it right. ^
Ⓚ	QUERY FOR AUTHOR	Ⓚ was Your proof read by ^
[/]	INSERT BRACKETS	[/] The Smith girl ^ ^
</>	INSERT PARENTHESES	</> Your proof. ^ ^
1/m	INSERT 1-EM DASH	1/m Your proof. ^
□	INDENT 1 EM	□ Your proof
▢	INDENT 2 EMS	▢ Your proof.
▣	INDENT 3 EMS	▣ Your proof.

Heart and Circulatory Physiology 2008

Published by The American Physiological Society

This is your reprint order form or pro forma invoice

(Please keep a copy of this document for your records. This form is not for commercial ordering.)

IMPORTANT Order form must be returned within 48 hours of receipt to avoid late charges. Orders received after 48 hours will be charged an additional fee of 25%. Orders received after 30 days will be charged an additional 50%. Reprints containing color figures are available only if ordered before the journal is printed. It is the policy of Cadmus Reprints to issue only one invoice per order.
Please print clearly. Please return form whether reprints are ordered or not.

Author Name _____
Title of Article _____
Issue of Journal _____ Reprint # 3401006 Manuscript # H-00617-2008 Publication Date _____
Number of Pages _____ Color in Article? Yes / No (Please Circle) Symbol AHEART

Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.

Order and Shipping Information

Reprint Costs (Please see page 2 of 2 for reprint costs/fees.)

_____ Number of reprints ordered \$ _____
_____ Number of color reprints ordered \$ _____
Subtotal \$ _____
Add appropriate sales tax/GST to subtotal \$ _____
First address included, add \$32 for each additional shipping address \$ _____

Publication Fees (Please see page 2 for fees and descriptions.)

Page Charges: \$70 per journal page \$ _____
Color Figures: \$400 per color figure \$ _____
Hard copy color proof: \$75 per figure \$ _____
Toll-Free Link: \$150 \$ _____

Member No. _____ Member Signature _____
Total Publication Fees \$ _____
TOTAL TO REMIT \$ _____

Shipping Address (cannot ship to a P.O. Box) Please Print Clearly

Name _____
Institution _____
Street _____
City _____ State _____ Zip _____
Country _____
Quantity _____ Fax _____
Phone: Day _____ Evening _____
E-mail Address _____

Additional Shipping Address* (cannot ship to a P.O. Box)

Name _____
Institution _____
Street _____
City _____ State _____ Zip _____
Country _____
Quantity _____ Fax _____
Phone: Day _____ Evening _____
E-mail Address _____

* Add \$32 for each additional shipping address

Payment and Credit Card Details (FEIN #:541274108)

Enclosed: Personal Check _____
Institutional Purchase Order _____
Credit Card Payment Details _____

Checks must be paid in U.S. dollars and drawn on a U.S. Bank.

Credit Card: VISA Am. Exp. MasterCard

Card Number _____

Expiration Date _____

Signature: _____

Please send your order form and purchase order or prepayment made payable to:

Cadmus Reprints
P.O. Box 751903
Charlotte, NC 28275-1903

Note: Do not send express packages to this location, PO Box.

Invoice or Credit Card Information

Invoice Address Please Print Clearly

Please complete Invoice address as it appears on credit card statement

Name _____
Institution _____
Department _____
Street _____
City _____ State _____ Zip _____
Country _____
Phone _____ Fax _____
E-mail Address _____
Purchase Order No. _____

Cadmus will process credit cards and Cadmus Journal Services will appear on the credit card statement.

If you do not mail your order form, you may fax it to 410-820-9765 with your credit card information.

SIGNATURE REQUIRED: By signing this form the author agrees to accept responsibility for the payment of the mandatory page charges of \$70 per page, reprints ordered, as well as any color charges, late payments, and split shipment charges. If the charges are billed to an institution, the author must assume the responsibility for making the necessary arrangements for the issuance of a formal institutional purchase order. Otherwise, it is understood that the author will bear the cost of these charges. Failure to pay any of these agreed-upon charges could jeopardize future submissions.

AUTHOR Signature _____
Telephone _____

Fax _____
E-mail _____

Heart and Circulatory Physiology 2008

Published by The American Physiological Society

REPRINT AND PUBLICATION CHARGES; Author rates only. Not to be used for commercial ordering

Black and White Reprint Prices

Domestic (USA only)						
# of Pages	100	200	300	400	500	Addl 100's
1-4	\$226	\$316	\$405	\$495	\$583	\$82
5-8	\$307	\$464	\$624	\$782	\$939	\$141
9-12	\$396	\$602	\$813	\$1,018	\$1,226	\$158
13-16	\$475	\$751	\$1,027	\$1,303	\$1,581	\$263
17-20	\$552	\$890	\$1,226	\$1,564	\$1,896	\$322
21-24	\$642	\$1,038	\$1,432	\$1,827	\$2,222	\$377
25-28	\$720	\$1,187	\$1,651	\$2,114	\$2,578	\$442
29-32	\$813	\$1,334	\$1,869	\$2,401	\$2,935	\$507

Color Reprint Prices

Domestic (USA only)						
# of Pages	100	200	300	400	500	Addl 100's
1-4	\$331	\$526	\$720	\$915	\$1,108	\$188
5-8	\$413	\$674	\$939	\$1,202	\$1,463	\$246
9-12	\$501	\$812	\$1,128	\$1,438	\$1,751	\$263
13-16	\$580	\$961	\$1,343	\$1,723	\$2,106	\$367
17-20	\$657	\$1,101	\$1,541	\$1,983	\$2,420	\$427
21-24	\$748	\$1,247	\$1,747	\$2,248	\$2,747	\$482
25-28	\$825	\$1,396	\$1,965	\$2,535	\$3,104	\$547
29-32	\$918	\$1,544	\$2,185	\$2,821	\$3,460	\$611

International (includes Canada and Mexico)						
# of Pages	100	200	300	400	500	Addl 100's
1-4	\$255	\$356	\$462	\$564	\$669	\$95
5-8	\$348	\$534	\$721	\$907	\$1,094	\$170
9-12	\$452	\$699	\$957	\$1,201	\$1,455	\$201
13-16	\$545	\$878	\$1,211	\$1,545	\$1,880	\$321
17-20	\$637	\$1,046	\$1,455	\$1,862	\$2,265	\$392
21-24	\$739	\$1,220	\$1,702	\$2,183	\$2,664	\$462
25-28	\$835	\$1,398	\$1,961	\$2,528	\$3,088	\$542
29-32	\$939	\$1,577	\$2,226	\$2,873	\$3,521	\$622

International (includes Canada and Mexico)						
# of Pages	100	200	300	400	500	Addl 100's
1-4	\$360	\$567	\$778	\$986	\$1,196	\$200
5-8	\$454	\$745	\$1,038	\$1,330	\$1,621	\$275
9-12	\$558	\$911	\$1,274	\$1,623	\$1,984	\$306
13-16	\$651	\$1,090	\$1,528	\$1,968	\$2,409	\$427
17-20	\$744	\$1,259	\$1,774	\$2,287	\$2,795	\$498
21-24	\$845	\$1,433	\$2,021	\$2,608	\$3,195	\$568
25-28	\$942	\$1,611	\$2,281	\$2,954	\$3,620	\$649
29-32	\$1,047	\$1,790	\$2,546	\$3,300	\$4,055	\$728

Minimum order is 100 copies. For orders larger than 500 copies, please consult Cadmus Reprints at 800-407-9190.

Page Charges

\$70 per journal page for all pages in the article, whether or not you buy reprints.

Color

Reprints containing color figures are available. If your article contains **color**, you must pay subsidized color charges of \$400/fig. (reprint charge is \$1000/fig for those who do not pay promptly), whether or not you buy reprints. These **color charges are waived for APS Members who are the first or last author of the paper**. If you requested a **hard copy color figure proof** when you reviewed your S-proof, the charge is \$75.

Shipping

Shipping costs are included in the reprint prices. Domestic orders are shipped via FedEx Ground service. Foreign orders are shipped via an expedited air service. The shipping address printed on an institutional purchase order always supersedes.

Multiple Shipments

Orders can be shipped to more than one location. Please be aware that it will cost \$32 for each additional location.

State Sales Tax and Canadian GST

Residents of Virginia, Maryland, Pennsylvania, and the District of Columbia are required to add the appropriate sales tax to each reprint order. For orders shipped to Canada, please add 6% Canadian GST unless exemption is claimed.

Late Order Charges

Articles more than 90 days from publication date will carry an additional charge of \$5.67 per page for file retrieval.

TOLL-FREE LINK

A link can be created from a url of your choice to your article online so that readers accessing your article from your url can do so without a subscription. The cost is \$150. This is especially useful if your article contains electronic supplemental material. For more information, please click on this link:

<http://www.the-aps.org/publications/sprooflink.pdf>

Ordering

Please fax your order form and purchase order to 410-820-9765. Prepayment of **checks** should be mailed to address below:

Cadmus Reprints
P.O. Box 751903
Charlotte, NC 28275-1903

Note: Do not send express packages to this location.

FEIN #: 541274108

Please direct all inquiries to:

Mary Leonard
800-407-9190 (toll free number)
410-819-3912 (direct number)
410-820-9765 (FAX number)
LeonardM@cadmus.com

Reprint Order Forms and Purchase Orders or prepayments must be received 48 hours after receipt of form.

Please return this form even if no reprints are ordered.

Formation and function of ceramide-enriched membrane platforms with CD38 during M₁-receptor stimulation in bovine coronary arterial myocytes

AQ:1

Su-Jie Jia,* Si Jin,* Fan Zhang, Fan Yi, William L. Dewey, and Pin-Lan Li

Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

Submitted 11 June 2008; accepted in final form 20 August 2008

AQ:2

Jia S-J, Jin S, Zhang F, Yi F, Dewey WL, Li P-L. Formation and function of ceramide-enriched membrane platforms with CD38 during M₁-receptor stimulation in bovine coronary arterial myocytes. *Am J Physiol Heart Circ Physiol* 295: H000–H000, 2008. First published August 22, 2008; doi:10.1152/ajpheart.00617.2008.—CD38 contains an ADP ribosylcyclase domain that mediates intracellular Ca²⁺ signaling by the production of cyclic ADP-ribose (cADPR), but the mechanisms by which the agonists activate this enzyme remain unclear. The present study tested a hypothesis that a special lipid-raft (LR) form, ceramide-enriched lipid platform, contributes to CD38 activation to produce cADPR in response to muscarinic type 1 (M₁) receptor stimulation in bovine coronary arterial myocytes (CAMs). By confocal microscopic analysis, oxotremorine (Oxo), an M₁ receptor agonist, was found to increase LR clustering on the membrane with the formation of a complex of CD38 and LR components such as GM₁, acid sphingomyelinase (ASMase), and ceramide, a typical ceramide-enriched macrodomain. At 80 μM, Oxo increased LR clustering by 78.8%, which was abolished by LR disruptors, methyl-β-cyclodextrin (MCD), or filipin. With the use of a fluorescence resonance energy transfer (FRET) technique, 15.5 ± 1.9% energy transfer rate (vs. 5.3 ± 0.9% of control) between CD38 and LR component, ganglioside M₁ was detected, further confirming the proximity of both molecules. In the presence of MCD or filipin, there were no FRET signals detected. In floated detergent-resistant membrane fractions, CD38 significantly increased in LR fractions of CAMs treated by Oxo. Moreover, MCD or filipin attenuated Oxo-induced production of cADPR via CD38. Functionally, Oxo-induced intracellular Ca²⁺ release and coronary artery constriction via cADPR were also blocked by LR disruption or ASMase inhibition. These results provide the first evidence that the formation of ceramide-enriched lipid macrodomains is crucial for Oxo-induced activation of CD38 to produce cADPR in CAMs, and these lipid macrodomains mediate transmembrane signaling of M₁ receptor activation to produce second messenger cADPR.

lipid microdomains; sphingolipid; lipid mediator; smooth muscle; calcium signaling

CYCLIC ADP-RIBOSE (cADPR), an alternative Ca²⁺ mobilizing second messenger to inositol 1,4,5-trisphosphate [Ins(1,4,5)P₃], has been indicated to participate in the regulation of many cell functions or physiological processes, including insulin secretion, egg fertilization, cell proliferation, nitric oxide-induced Ca²⁺ movement, lymphocyte activation, and neural activity (13, 37). Recent studies in our laboratory and by others have reported that in vascular smooth muscle, cADPR contributes to the Ca²⁺ release from the sarcoplasmic reticulum (SR) induced by Ins(1,4,5)P₃-independent agonists, such as acetylcholine,

oxotremorine (Oxo), 5-hydroxytryptamine, angiotensin II, and endothelin, leading to the contraction of arterial smooth muscle via ryanodine receptor (RyR)-mediated intracellular Ca²⁺ release (5, 11, 26). This cADPR/RyR-mediated Ca²⁺ signaling is now recognized as a fundamental mechanism regulating vascular function. CD38 is one of the important enzymes responsible for the production and metabolism of cADPR in vascular cells, and therefore CD38/cADPR pathway is considered as an important signaling pathway in the regulation of vasomotor responses (32). It is believed that the activation of this enzyme participates, at least in part, in Oxo-induced vasoconstriction and other receptor-mediated agonist responses (21, 38). However, the precise mechanism by which CD38 is activated by various agonists still remains unclear. Since this enzyme has been shown to localize outside cells constitutively in many studies, it is very puzzling how this enzyme could produce an intracellular second messenger to exert its signaling action.

Recently, lipid-raft (LR) clustering on the cell membrane is emerging as a novel mechanism mediating the transmembrane signaling in response to various stimuli in a variety of cell types, including lymphocytes, endothelial cells, and neurons (15, 16, 41). It has been shown that clustered membrane LRs form membrane signaling platforms, in particular, the ceramide-enriched platforms or macrodomains. These lipid platforms may recruit or aggregate various signaling molecules such as trimeric G proteins, small G proteins, sphingomyelin (SM), tyrosine kinases, NADPH oxidase subunits, phosphatases, and many others, resulting in the activation of different signaling pathways. Recent studies have reported that LRs are closely associated with the CD38 pathway in various lymphocytes and these LRs may be responsible for endocytosis of CD38 and the activation of certain signaling pathways (35, 46). However, the identity of these LRs remains unclear, and it is also unknown whether LRs during its clustering are involved in cADPR-mediated Ca²⁺ signaling. In previous studies, a rapid activation and translocation of acid sphingomyelinase (ASMase) into LRs were observed in response to various stimuli such as FasL, TNF-α, and endostatin (29, 33, 41). Moreover, our previous work also demonstrated that lysosomal ASMase contributes to the formation of LR redox signaling platforms by hydrolyzing SM to produce ceramide, which produces ceramide-enriched macrodomains or LR platforms, ultimately resulting in endothelial dysfunction (18). Based on these observations, the present study was designed to test the hypothesis that ceramide-enriched LR platforms may mediate an agonist-induced transmembrane signaling of CD38 and thereby participate in

* S.-J. Jia and S. Jin contribute equally to this work.

Address for reprint requests and other correspondence: P.-L. Li, Dept. of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth Univ., 410 N. 12th St., Richmond, VA 23298 (e-mail: pli@vcu.edu).

AQ:5

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

AQ:5

Oxo-induced CD38 activation to produce cADPR in coronary arterial myocytes (CAMs). To test this hypothesis, we first characterized the formation of ceramide-enriched LR clusters in CAMs in response to Oxo. We then examined the role of this LR clustering in aggregation and activation of CD38 in the membrane of these cells and explored the related molecular mechanisms mediating Oxo-induced ceramide production and LR platforms formation via ASMase/ceramide pathway. Furthermore, we determined whether this ceramide-enriched signaling platform with activated CD38 contributes to Ca^{2+} release in CAMs, ultimately leading to the constriction of coronary arteries.

MATERIALS AND METHODS

Bovine hearts were purchased from a local slaughterhouse and were used to isolate coronary artery smooth muscle cells. No living animals were used for the present study, and therefore there was no concern over vertebrate animal use.

Cell culture. Bovine CAMs were cultured as described previously (3, 42–45). Briefly, coronary arteries dissected from bovine hearts were first rinsed with 5% FBS in medium 199 containing 25 mM HEPES with 1% penicillin, 0.3% gentamycin, and 0.3% nystatin and then cut into segments, and the lumen was filled with 0.4% collagenase in medium 199. After 30 min of incubation at 37°C, the arteries were flushed with medium 199. The strips of denuded arteries were placed into gelatin-coated flasks with medium 199 containing 10% FBS with 1% L-glutamine, 0.1% tylosin, and 1% penicillin-streptomycin. CAMs migrated to the flasks within 3–5 days. Once cell growth was established, the arteries were removed and growing CAMs were cultured in medium 199 containing 20% FBS. The identification of CAMs was based on positive staining by an anti- α -actin antibody. Cells of passages 2–4 were used in the present study.

Confocal analysis of LR clusters in CAMs. Individual LRs are too small (~50 nm in diameter) to be resolved by standard light microscopy; however, if LR components are cross-linked in living cells, clustered raft protein and lipid components can be visualized by fluorescence microscopy. For microscopic detection of LR platforms, CAMs were grown on glass coverslips and then treated with different doses of Oxo (20–120 μM ; Sigma, St. Louis, MO) for 15 min to induce clustering of LRs. In additional groups of cells, LR disruptors filipin (1 μg ; Sigma) or methyl- β -cyclodextrin (MCD; 100 μM ; Sigma) or an ASMase inhibitor desipramine (Des, 10 μM ; Sigma) were added and incubated for 20 min before Oxo stimulation.

These cells were then washed in cold PBS and fixed for 10 min in 4% paraformaldehyde and blocked with 1% BSA in TBS for 30 min. GM₁ gangliosides enriched in LRs were stained by Alexa488-labeled cholera toxin B (Alexa488-CTXB, 1 $\mu\text{g}/\text{ml}$) (Molecular Probes, Eugene, OR). The stained cells were then extensively washed, fixed in 4% paraformaldehyde for another 10 min, and mounted on glass slide with Vectashield mounting media (Vector, Burlingame, CA). The staining of LRs was visualized using an Olympus scanning confocal microscope (Olympus, Tokyo, Japan) at excitation/emission of 495/519 nm. The patch or macrodomain formation of Alexa488-labeled CTX, namely, gangliosides complex, represents the clusters of LR. Clustering was defined as one or several intense spots or patches, rather than diffuse fluorescence on the cell surface, whereas a vast majority of unstimulated cells displayed a homogenous or diffuse distribution of fluorescence throughout the membrane. In each experiment, the presence or absence of clustering in 200 cells was independently scored by unwitting researchers after the criteria for positive spots of fluorescence were specified. Cells that displayed a homogenous distribution of fluorescence were indicated negative. Results were given as the percentage of cells showing one or more clusters after indicated treatments.

Colocalization of LR clusters and CD38, ASMase, or ceramide in CAMs. For dual-staining detection of the colocalization of LRs and ceramide or ASMase, CAMs were first incubated with Alexa488-labeled CTX as described in *Confocal analysis of LR clusters in CAMs* and then with mouse anti-ceramide IgM antibody (1:200; Alexis Biochemicals, San Diego, CA) or goat anti-ASMase antibodies (1:200; Santa Cruz, Santa Cruz, CA) separately in different groups of cells, which was followed by Cy3-conjugated anti-mouse or Texas red-labeled anti-goat (Molecular Probes, Eugene, OR) secondary antibody as needed, respectively.

Fluorescence resonance energy transfer measurement. To further determine the molecular complex in LR clusters, CAMs were stained with tetramethylrhodamine isothiocyanate (TRITC)-labeled CTXB and FITC-labeled anti-CD38 antibody and then visualized under a confocal microscope. An acceptor bleaching protocol was employed to measure the fluorescence resonance energy transfer (FRET) efficiency (31, 36). After the prebleaching images were normally taken, the laser intensity at an excitation wavelength of the acceptor (TRITC) was increased from 50 to 98 W/cm² and continued to excite the sample cells for 2 min to bleach the acceptor fluorescence. After the excitation intensity was adjusted back to 50 W/cm², the postbleaching image was then taken. The FRET images were obtained by the subtraction of the prebleaching image from the postbleaching image and shown in blue color. After the measurement of FITC fluorescence intensity in images acquired at pre- and postbleaching as well as the FRET images, a FRET efficiency was calculated through the following formula: $E = (\text{FITC}_{\text{post}} - \text{FITC}_{\text{pre}}) / \text{FITC}_{\text{post}} \times 100\%$ as described previously (14), where FITC fluorescence intensity was obtained from labeling of CD38.

Assay of ASMase activity. The activity of ASMase in CAMs was determined as described in our previous studies (39). Briefly, homogenates from CAMs were centrifuged at 1,000 g for 10 min to remove cell nuclei, and 50 μl of the supernatant homogenate were used for enzyme activity analysis. The ASMase activity was measured using radiolabeled substrate, [*N*-methyl-¹⁴C]-SM (Perkin-Elmer Life Sciences). The assay mixture contained 100 nmol of SM (1,154 dpm/nmol) in 100 mM sodium acetate (pH 5.0), 0.1% Triton X-100, and 0.1 mM EDTA. After incubation at 37°C for 1 h, the reaction was stopped by adding 1.5 ml of chloroform:methanol (2:1 vol/vol), followed by an addition of 0.2 ml of water. A portion of the aqueous phase was transferred to scintillation vials and counted in a liquid scintillation counter for radioactivity of the reaction product, [¹⁴C]choline phosphate.

Floation of membrane LR fractions. To isolate LR microdomain fractions from cell membrane, CAMs were lysed in 1.5 ml morpholinoethanesulfonic acid-buffered sample buffer containing (in $\mu\text{mol}/\text{l}$) 25 morpholinoethanesulfonic acid, 150 NaCl, 1 EDTA, 1 PMSF, and 1 Na₃VO₄ and a mixture of “complete” protease inhibitors and 1% Triton X-100 (pH 6.5). Cell extracts were homogenized by five passages through a 25-gauge needle. Homogenates were adjusted with 60% OptiPrep Density Gradient medium to 40% and overlaid with discontinuous 30% to 5% OptiPrep Density Gradient medium. Samples were centrifuged at 32,000 rpm for 30 h at 4°C using a SW32.1 rotor. Fractions were collected from top to bottom. For immunoblot analysis of LR-associated proteins, these fractions were precipitated by mixing with equal volume of 30% trichloroacetic acid and 30 min of incubation on ice. Precipitated proteins were spun down by centrifugation at 13,000 rpm at 4°C for 15 min. The protein pellet was carefully washed with cold acetone twice, air dried, and then resuspended in 1 mol/l Tris·HCl (pH 8.0), which was ready for immunoblot analysis.

Western blot analysis. For immunodetection of LR-associated proteins, 50 μl of resuspended proteins were subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, and blocked as described previously (41). The membrane was probed with primary monoclonal antibodies of anti-flotillin-1 (1:1,000, a LR marker proteins; BD Biosciences, San Jose, CA), anti-CD38 (1:1,000, BD Biosciences), or anti-ASMase (1:1,000, Santa Cruz) overnight at 4°C, followed by an

incubation with horseradish peroxidase-labeled anti-mouse or anti-goat IgG (1:5,000). The immunoreactive bands were detected by chemiluminescence methods according to the manufacturer's instruction and visualized on Kodak Omat film. The intensity of the immunoreactive bands was quantified by densitometry.

HPLC analysis of ADP-ribosyl cyclase activity in CAMs. To determine ADP-ribosyl cyclase activity, homogenates from CAMs (100 μ g protein) were incubated with 100 μ M β -nicotinamide guanine dinucleotide (β -NGD⁺) at 37°C for 90 min. β -NGD⁺ was used as a substrate to determine ADP-ribosyl cyclase activity because this enzyme is able to convert NGD into cyclic GDP-ribose (cGDPR) at the same reaction efficiency as working to convert β -NAD⁺ into cADPR, but cGDPR unlike cADPR may not be hydrolyzed by cADPR hydrolase. Therefore, the use of β -NGD⁺ will maximally detect the production of this enzyme by the blockade of a further hydrolysis of its products. After the reaction, the mixtures were centrifuged at 4°C through an Amicon microultrafilter at 13,800 g to remove proteins, and then cGDPR was analyzed by HPLC with a fluorescence detector (Agilent 1100 series HPLC system and G1321 spectrofluorometer). The excitation wavelength of 300 nm and the emission wavelength of 410 nm were used to detect cGDPR produced via cADP-ribosyl cyclase. All HPLC data were collected and analyzed by an Agilent Chemstation. Nucleotides were resolved on a 3- μ m Supelcosil LC-18 column (4.6 \times 150 mm) with a 5- μ m Supelcosil LC-18 guard column (4.6 \times 20 mm, Supelco, Bellefonte, PA). The injection volume was 20 μ l. The mobile phase consisted of 150 mM ammonium acetate (pH 5.5) containing 5% methanol (*solvent A*) and 50% methanol (*solvent B*). The solvent system was a linear gradient of 5% *solvent B* in *A* to 30% *solvent B* in *A* over 1 min, held for 25 min, and then increased to 50% *solvent B* over 1 min. The flow rate was 0.8 ml/min. Peak identities were confirmed by the comigration with known standards. Quantitative measurements were performed by the comparison of a known concentration of standards.

Measurement of intracellular Ca²⁺ concentration in CAMs. Determination of intracellular Ca²⁺ concentration in CAMs was performed to determine the contribution of LR-CD38 platforms to cADPR-mediated Ca²⁺ signaling. Briefly, CAMs were cultured on a glass coverslip to reach ~60–70% confluence, and the culture medium was then removed. The cells were next loaded with fura-2 acetoxymethyl ester (fura-2 AM, 5 μ M; Molecular Probes) at 37°C for 30 min and incubated for 20 min to allow a complete hydrolysis of intracellular fura-2 AM to fura-2 in a Ca²⁺-free Hanks' buffered saline solution containing (in mM) 137 NaCl, 5.4 KCl, 4.2 NaHCO₃, 3 Na₂HPO₄, 0.4 KH₂PO₄, 0.5 MgCl₂, 0.8 MgSO₄, 10 glucose, and 10 HEPES (pH 7.4). The coverslip was mounted horizontally on a Nikon Diaphoto TMD inverted microscope (Nikon, Japan). Oxo (80 μ M) was added to the bath solution to induce Ca²⁺ release. This dose of Oxo was used in our several previous studies where muscarinic type 1 (M₁) receptor was activated and cADPR and related Ca²⁺ release were produced in CAMs (11, 38). To examine the specificity of Oxo and the role of LRs in Oxo-induced Ca²⁺ release, the cells were pretreated for 15 min with 8-bromo-cADPR (8-Br-cADPR, a cADPR antagonist at 30 μ M), LR disruptors, filipin (1 μ g) or MCD (100 μ M), or an ASMase inhibitor, Des (10 μ M), and then Oxo-induced Ca²⁺ release was redetermined. All these experiments were conducted in Ca²⁺-free Hanks' buffer. A SPOT digital camera (SPOT RT Monochrome; Diagnostic Instruments) was used to record fura-2 fluorescence images. Metafluor imaging and analysis software (Universal Imaging) was used to acquire, digitize, and store the images.

Vascular reactivity in perfused small coronary arteries in vitro. Vascular reactivity in isolated perfused and pressurized small bovine coronary artery was measured as described previously (11). The intramural coronary arteries (<300 μ m in diameter) were dissected from fresh cow hearts and assembled between two glass tips. After a 60-min equilibration period under the transmural pressure of 60 mmHg, Oxo (80 μ M) was added to the bath solution to induce vasoconstriction. When Oxo-induced contraction reached a stable

plateau, the internal diameters of the arteries were measured and recorded. To examine the contribution of ASM/ceramide and LR/CD38 pathway to Oxo-induced vasoconstriction, the arteries were pretreated for 20 min with one of the following compounds: nicotinamide (Nicot; 6 mM; an inhibitor of ADP-ribosyl cyclase), 8-Br-cADPR (30 μ M; a cADPR antagonist), LR disruptors, MCD (100 μ M), and filipin (1 μ g), or an ASMase inhibitor, Des (10 μ M). Oxo (80 μ M) was added and the vasoconstrictor response was observed as described in the protocol without these components. The contractile responses to Oxo were expressed as the percent reduction in vascular internal diameters.

Statistics. Data are presented as means \pm SE. Significant differences between and within multiple groups were examined using ANOVA for repeated measures, followed by Duncan's multiple-range test. Student's *t*-test was used to determine the significance of difference in two groups of experiments. *P* < 0.05 was considered statistically significant.

RESULTS

Cofocal microscopy of Oxo-induced LR clustering in CAMs.

Figure 1A presents the typical fluorescent confocal microscopic images depicting Alexa488-CTX-labeled patches on the cell membrane of CAMs. Under the resting condition (control), there was only a diffuse fluorescent staining on the cell membrane, indicating a possible distribution of a single LR. When CAMs were incubated with Oxo, some large fluorescent dots or patches were detected on the cell membrane, indicating LR patches or macrodomains. Figure 1B summarized the effects of different doses of Oxo on the LR clustering by counting these LR clusters or patches. It was found that under control condition, CAMs displayed a small percentage with LR clustering (19.6 \pm 3.9%). After these cells were stimulated with Oxo, LR-clustered positive cells increased significantly in a dose-dependent manner. At 80 μ M, Oxo increased LR clustering by 65.7 \pm 9.4% (*P* < 0.05, *n* = 5). This Oxo-induced LR clustering effect was abolished by LR disruptors, MCD and filipin, respectively. Des, a selective inhibitor of ASMase, also inhibited this Oxo-induced LR clustering.

Oxo-induced FRET between CD38 and LR component, GM₁. FRET was detected by FITC-labeled anti-CD38 antibody and TRITC-labeled CTX. As shown in Fig. 2A, *top*, the green image showed the FITC-labeled anti-CD38 antibody, whereas the red image showed a labeling of GM₁ by TRITC-CTX. The overlaid image mainly showed colocalization, but a subtraction of pre- from postimage on FITC image represents FRET in that we used an acceptor (TRITC) bleaching protocol. In this protocol, TRITC was bleached, and therefore the normally weakened FITC signal due to energy transferring into neighbor molecules could be enhanced. The increase in the FITC-labeled CD38 signal indicates the increase of FRET efficiency, which was derived from the blockade of acceptance of photons by TRITC (bleached). Under control conditions, when two images were overlaid, there was no yellow spots or patches detected. When CAMs were stimulated by Oxo, yellow spots were seen, which represent a colocalization of GM₁ and CD38 (*right*). The green fluorescence intensity of FITC-anti-CD38 antibody (*middle*) increased after the acceptor of TRITC labeling CTX was bleached during Oxo stimulation, whereas the red fluorescence intensity of TRITC labeling CTX almost disappeared due to bleaching. Under this condition, there was no yellow spot detectable in the overlaid image. Figure 2A, *bottom*, showed a subtracted image between the pre- and




Fig. 1. Oxtremorine (Oxo)-induced lipid-raft (LR) clustering in coronary arterial myocytes (CAMs) membrane in the absence or presence different LR disruptors. *A*: representative images of control and Oxo-stimulated CAMs stained with Alexa488-cholera toxin B (CTXB). *B*: CAMs were stimulated with different doses of muscarinic type 1 (M₁) receptor agonist, Oxo (20–120 μM) for 15 min to induce LR clustering. *C*: CAMs were stimulated with Oxo (80 μM, 15 min) before and after pretreatment with LR disruptors, methyl-β-cyclodextrin (MCD; 100 μM), filipin (1 μg), or with a selective acid sphingomyelinase (ASMase) inhibitor, desipramine (Des, 10 μM) for 20 min. Shown is the percentage of cells displaying LR clustering. Values presented are means ± SE (*n* = 5 experiments with analysis from more than 1,000 cells). **P* < 0.05 and ***P* < 0.01 vs. control; ###*P* < 0.01 vs. Oxo-treated group.

postacceptor bleaching, and the blue color intensity represented increased FITC fluorescence due to FRET. Figure 2B showed the summarized results of FRET analysis. When compared with control (5.3 ± 0.9%), the efficiency of FRET in the Oxo-treated group of CAMs increased significantly to 15.5 ± 1.9% (*P* < 0.01, *n* = 5). When a same molecule of the cells (CD38) was stained by FITC-labeled primary antibody followed by TRITC-labeled secondary antibody and subjected to FRET protocol, a maximal FRET efficiency was 25% (data not shown). Pretreatment with LR disruptors, MCD or filipin, decreased the FRET efficiency remarkably. In addition, FRET efficiency was also inhibited by Des, an ASMase inhibitor (Fig. 2B).

CD38 aggregation in isolated LR fractions. By Western blot analysis, the expression of flotillin-1, a LR specific marker,

was primarily found in the fractions between the 5% and 30% gradients, which was referred to LR fractions previously (27). As shown in Fig. 3, the ratio of CD38 levels in LR fractions to those in other fractions were summarized, because their clustering in LR fractions of cell membrane, rather than increase in expression, is comparable. CD38 could be detected in most of the membrane fractions from CAMs under control conditions. There was a marked increase in CD38 protein in LR fractions when these cells were stimulated by Oxo. However, when the cells were pretreated by MCD, filipin, or Des, a Oxo-induced increase in CD38 in LR fractions was significantly blocked.

Contribution of ceramide and ASMase to Oxo-induced LR clustering. To examine whether ASMase/ceramide is involved in Oxo-induced LR clustering and whether Oxo-induced LR clustering forms ceramide-enriched macromolecules, we stained CAMs with Alexa488-CTX and Texas red-conjugated anti-ASMase antibody or Cy3-labeled ceramide. As shown in Fig. 4, Oxo stimulation caused an aggregation of both ceramide and ASMase in LR clusters (colocalized with CTX-labeled GM₁), which were exhibited by yellow dots




Fig. 2. Fluorescence resonance energy transfer (FRET) between a fluorophore pair, FITC (donor) and tetramethylrhodamine isothiocyanate (TRITC; acceptor) labeled anti-CD38 antibody and LR component, GM₁ binder, CTXB, respectively. Acceptor (TRITC) bleaching protocol was applied to detect the FRET efficiency. *A*: typical images depicting FRET between FITC-conjugated anti-CD38 antibody and TRITC-conjugated CTXB in a control and Oxo-treated CAM, respectively. *B*: means ± SE of FRET efficiency, and LR disruptors, MCD (100 μM), filipin (1 μg) or ASMase inhibitor Des (10 μM) attenuated Oxo-induced increase in FRET efficiency. ***P* < 0.01 vs. control; ###*P* < 0.01 vs. Oxo-treated group.




Fig. 3. Western blot analysis of CD38 and ASMase in LR fractions isolated from CAMs stimulated by Oxo. *A*: CAMs were treated with Oxo (80 μ M, 15 min) alone or with 20-min pretreatment of MCD (100 μ M), filipin (1 μ g), or Des (10 μ M). Fractions between 5% and 30% gradients were designated as LRs as indicated by the marker protein flotillin-1. The blot pattern for CD38 and ASMase represents 5 individual experiments. *B*: quantified data of the ratio of CD38 or ASMase in LR fraction to that of total in each membrane blot (LR/Total). It was found that Oxo stimulated both CD38 and ASMase aggregation into LR fractions, which was significantly attenuated by LR disruptors and ASMase inhibitors. * $P < 0.05$ vs. control; # $P > 0.05$ vs. control ($n = 5$ experiments).

AQ: 4

or patches (*right*). When these cells were pretreated by either MCD or filipin, both CTX clusters (Alexa488 green fluorescence) and aggregated ASMase (Texas red fluorescence) or ceramide (Cy3 fluorescence) were no longer observed. Correspondingly, in isolated LR fractions, ASMase was found to be increased in CAMs treated with Oxo, whereas in other fractions, ASMase contents remained unchanged or reduced. However, in the presence of LR disruptors, MCD or ASMase inhibitor, Des, this redistribution of ASMase induced by Oxo was abolished (Fig. 3).

To further confirm whether ASMase is involved in Oxo-induced LR clustering, we directly measured ASMase activity in CAMs. As shown in Fig. 5A, Oxo treatment of CAMs for 15 min markedly increased ASMase activity in CAMs, which was

F5

substantially inhibited by ASMase inhibition with Des. However, LR disruptors, MCD or filipin, only had minimal inhibitory effect on Oxo-induced enhancement of ASMase activity, suggesting that ASMase activation may precede LR clustering.

Role of ceramide-enriched lipid platforms with CD38 in Oxo-induced increase in ADP-ribosylcyclase activity in CAMs. To explore the functional significance of ceramide-enriched lipid platforms with CD38 in CAMs, we directly observed the Oxo-induced increase in CD38 activity by HPLC in these cells before and after a pretreatment with LR disruptors, MCD or ASMase inhibitor, Des. As shown in Fig. 5B, the conversion rate of β -NGD to cGDPR was 43.1 ± 1.9 under control conditions. When cells were incubated with Oxo, the rate was increased significantly (57.6 ± 3.9). Pretreatment of CAMs with ADP-ribosylcyclase inhibitor, Nicot, significantly inhibited Oxo-induced production of cADPR. MCD and filipin also inhibited the effects of Oxo significantly.

Association of ceramide-enriched lipid-CD38 platforms with Oxo-induced intracellular Ca^{2+} release in CAMs. To further determine the role of ceramide-enriched lipid-CD38 platforms in the regulation of intracellular Ca^{2+} release, we examined Oxo-induced intracellular Ca^{2+} release in CAMs under control conditions and when they were treated with LR disruptors, MCD or filipin, and ASMase inhibitor, Des. In Fig. 6A, typical microscopic digitalized signal plots of Ca^{2+} release within CAMs bathed in Ca^{2+} -free solution are presented. It is clear that in the presence of 8-Br-cADPR (a cADPR antagonist), Des, MCD or filipin, Oxo-induced Ca^{2+} release in CAMs was significantly reduced compared with Oxo

F6




Fig. 4. Confocal microscopic analysis of ceramide (Ceram) and ASMase colocalization in LR clusters in CAMs. *A*: the cells stained with Texas red (TR)-conjugated anti-ASMase antibody and Alexa488 (A1488)-CTXB. *B*: the cells stained with Cy3-conjugated anti-ceramide antibody and Alexa488-CTXB. Ceramide and ASMase were found to be colocalized with LR marker when CAMs were stimulated by Oxo. This Oxo-induced colocalization can be blocked by pretreatment of the cells with LR disruptors (MCD or filipin) and ASMase inhibitor, Des.

COJ06




Fig. 5. Effects of Oxo on ASMase and ADP-ribosylcyclase activity in CAMs in the absence or presence of LR disruptors. *A*: summarized ASMase activity of CAMs treated with Oxo (80 μ M, 15 min) alone or with 20-min pretreatment of MCD (100 μ M), filipin (1 μ g), or Des (10 μ M). Values are means \pm SE of 5 experiments. Prot, protein. ** P < 0.01 vs. control; # P < 0.05 vs. Oxo-treated group. *B*: summarized ADP-ribosylcyclase activity of CAMs treated with Oxo (80 μ M, 15 min) alone or with 20-min pretreatment of MCD (100 μ M), filipin (1 μ g), or nicotinamide (Nicot; 6 mM) or Des (10 μ M). Values are means \pm SE from 5 experiments. ** P < 0.01 vs. control (Ctrl); # P < 0.05 vs. Oxo-treated group; ## P < 0.01.

stimulation alone. Calculated Ca^{2+} concentrations under different conditions are presented in Fig. 6B. In response to Oxo stimulation, intracellular Ca^{2+} concentration increased from 149.8 ± 32.7 to 495.0 ± 130.6 nM in CAMs. This Oxo-induced increase in intracellular Ca^{2+} levels could be attenuated or blocked by inhibition of LR clustering or formation of ceramide-enriched platforms either with LR disruptors or ASMase inhibitor.

Role of ceramide-enriched lipid platforms with CD38 in Oxo-induced vasoconstriction. Consistent with our previous reports (11, 43), we found that in the presence of Nicot or 8-Br-cADPR, the Oxo-induced contraction of small coronary arteries was significantly attenuated. The maximal contraction decreased from $47.2 \pm 6.8\%$ to $21.1 \pm 4.2\%$ or $27.3 \pm 4.8\%$, respectively ($n = 5$). In the presence of MCD or filipin, the Oxo-induced contraction was also significantly reduced to a very similar extent to that induced by Nicot or 8-Br-cADPR. When ASMase inhibitor, Des, was used to treat the coronary

arteries, the maximal contraction induced by Oxo decreased from $47.2 \pm 6.8\%$ to $26.5 \pm 3.9\%$ ($n = 5$) (Fig. 6C).

DISCUSSION

The main findings of the present study are that 1) Oxo induced LR clustering in CAMs as shown by the formation of larger membrane LR patches as detected by confocal microscopy; 2) Oxo induced an aggregation of CD38 in LR clusters with enriched ceramide, which resulted in the increased activity of CD38 as ADP-ribosylcyclase, and disruption of LRs inhibited the effects of Oxo on this enzyme activity; and 3) blockade of ASMase/ceramide inhibited Oxo-induced LR clustering and consequent CD38 activation and cADPR pro-




Fig. 6. Association of ceramide-enriched lipid-CD38 platforms with Oxo-induced intracellular Ca^{2+} release in CAMs and vessel constriction in small coronary arteries. *A*: representative recording of fura-2 Ca^{2+} signals by a high speed wavelength switch microscopic imaging system. F340/F380, emission fluorescence ratio with excitation at 340 and 380 nm. *B*: summarized intracellular free Ca^{2+} level in CAMs treated with Oxo (80 μ M, 15 min) alone or with 20-min pretreatment of MCD (100 μ M), filipin (1 μ g), 8-bromo-cADPR (8-Br; 30 μ M), or Des (10 μ M). Values are means \pm SE from 5 experiments. $[Ca^{2+}]_i$, intracellular Ca^{2+} concentration. *C*: summarized data showing the constriction of small coronary arteries treated with Oxo (80 μ M, 15 min) alone or with 20 min pretreatment of MCD (100 μ M), filipin (1 μ g), or Nicot (6 mM) or Des (10 μ M). Values are means \pm SE of 5 experiments. * P < 0.05 vs. Oxo-treated group.

duction, whereby an Oxo-induced increase in intracellular Ca^{2+} release and vasoconstriction was significantly attenuated. These results support our hypothesis that ceramide-enriched LR platforms mediate Oxo-induced transmembrane signaling of CD38 and thereby activate its ADP-ribosylcyclase to produce cADPR in CAMs.

Despite the increasing evidence that cADPR signaling becomes an essential mechanism in the regulation of the intracellular Ca^{2+} level in a variety of mammalian cells (6, 19), so far it remains unknown what mechanism mediates cADPR production in response to various agonists or stimuli and how a transmembrane signaling upon agonist stimulation occurs to activate cADPR producing enzyme and leads to responses of intracellular effectors. Moreover, there is evidence that CD38, a major enzyme producing cADPR in mammalian cells or tissues, is mainly present on the surface of cells serving as an ectoenzyme (1). It is imperative to know how an ectoenzyme could produce a second messenger to mediate intracellular Ca^{2+} signaling as an important function of cADPR. In the present study, we tested a novel hypothesis that LRs may form a signaling platform in vascular smooth muscle cells where CD38 can be aggregated and activated to produce cADPR when these cells are stimulated by agonists. This LRs-mediated transmembrane signaling may represent a novel mechanism initiating cADPR production and subsequent signaling cascade. The rationale of this hypothesis is based on the fact that the LRs may serve as anchoring platforms for organizing components of the signal transduction systems (8, 12, 30) and thereby participate in cellular signaling. In this regard, these LRs are known as specialized membrane microdomains rich of cholesterol and sphingolipids, which act as organizing centers by sequestering specific sets of proteins for different cellular activities such as membrane molecular trafficking and signal transduction (2). In vascular smooth muscle cells, LRs have been demonstrated to play an important role in several cell signaling pathways, such as agonist-induced Ca^{2+} release, phosphorylation of EGF receptor, and activation of RhoA (7, 17, 24). Using confocal microscopic analysis of GM_1 labeling by CTX as a marker of LR clusters, we found that under control conditions, LRs were diffusely distributed throughout the membrane of CAMs and that stimulation of these cells with Oxo resulted in a dose-dependent formation of CTX-positive fluorescent patches, which represented LR clusters or macrodomains. This suggests that LR clustering occurs in arterial smooth muscle cells in response to agonists such as Oxo. Given its well-known signaling role, this LR clustering may be of importance in mediating signal transduction or functional response in these vascular smooth muscles. Indeed, we demonstrated that this LR clustering was coupled to CD38 aggregation, as shown in confocal microscopic colocalization analysis, FRET detection, and membrane flotation of LR fractions. These LR-CD38 complex or membrane platforms may result in CD38 translocation and activation by agonists such as Oxo. To our knowledge, these results for the first time provide direct evidence that LRs are able to be clustered with aggregation of CD38 in vascular smooth muscle cells. In previous studies, this LR-mediated CD38 clustering was also reported in T-cells or B-cells, which participates in the regulation of T-cell or B-cell function by facilitating critical associations or interactions with other signaling molecules such as myosin heavy chain class II, CD9, N-Ras, Akt, Erk, Lck and CD3- ζ (4, 25, 46, 48).

However, the regulation of lymphocyte function by LR clustering has not been linked to its function of cADPR production and consequent Ca^{2+} mobilization.

In the present study, we provided further evidence that the aggregation of CD38 via LR clustering is involved in the activation of this enzyme to produce cADPR. By HPLC analysis of cGDPR production as an ADP-ribosyl cyclase activity, Oxo was found to significantly increase the activity of CD38 in CAMs, which was blocked by LR disruptors MCD and filipin. This suggests that LR clustering in these cells importantly contribute to the activation of CD38 as a cADPR-producing enzyme. To further determine the role of LR clustering in cADPR-mediated signaling, we addressed whether the activation of CD38 via LR clustering is attributed to Oxo-induced Ca^{2+} release response in CAMs. It has been reported that CD38 is a crucial pathway mediating Ca^{2+} release, and our previous work also demonstrated that cADPR-mediated Ca^{2+} mobilization represents an important signaling pathway participating in the Ca^{2+} regulation in vascular smooth muscle cells and in the vasoconstrictor response of coronary arteries when M_1 ACh receptor is activated (40). Consistent with these previous studies, the present study found that Oxo induced Ca^{2+} release from the SR in CAMs buffered in Ca^{2+} -free solution and that 8-Br-cADPR, an antagonist of cADPR, could block the action of Oxo. Interestingly, in the presence of LR disruptors, MCD or filipin, Oxo-induced Ca^{2+} release was substantially attenuated. In another series of experiments, we also examined the contribution of this LR clustering with CD38 to the vasoconstrictor response to Oxo. It was found that Oxo induced significant vasoconstriction with a maximal response of $47.2 \pm 6.8\%$ in perfused and pressurized small coronary arteries, which was significantly blocked by the LR disruptor, MCD or filipin. Taken together, these results indicate that LRs and their clustering importantly participate in the regulation of vascular function associated with CD38 activation and cADPR-mediated Ca^{2+} release in coronary arteries. To our knowledge, this represents the first report elucidating the functional association of LR clustering with CD38 activity to produce cADPR in the regulation of intracellular Ca^{2+} level of arterial myocytes and vasomotor response in coronary arteries. Previous studies also demonstrated the formation of LR-CD38 complex in lymphocytes in response to different stimuli (4, 25, 46). However, these studies did not demonstrate the correlation between the production of cADPR and agonist receptor functions when LR clustering occurred, but they assumed that CD38 may serve as a pleiotropic molecule in LR clusters, whose behavior or function is independent from its enzymatic activity in these cells (46). In some other studies, CD38 in LRs has been demonstrated as an interacting membrane molecule to facilitate the formation of different signaling complex in lymphocytes, which activates several different phosphorylation pathways to regulate cell proliferation or apoptosis (7, 48).

It should be noted that although Oxo or M_1 agonist may not be a major regulator of coronary vascular tone under physiological conditions, the use of this compound represents a prototype of agonists that stimulates cADPR production and induces vasoconstriction of bovine coronary arteries because bovine coronary arteries did not respond to angiotensin II or norepinephrine to produce vasoconstriction based on our experience working on this type of arteries for more than 10 years. Another comparable vasoconstrictor in these arteries is

to thromboxane A_2 mimetic, U-46619, a commonly used agonist in these bovine arteries, but this compound produces vasoconstriction through $\text{Ins}(1,4,5)\text{P}_3$ independent of LR. With respect to agonists or stimuli that use cADPR as second messengers, recent studies have demonstrated that there are Oxo in smooth muscle cells, cholecystokinin in pancreatic acinar cells, glucose in pancreatic β -cells, physiological contact or fertilization in the eggs, histamine and oxytocin in myometrial cells, and thrombin in platelets. Based on our results in using Oxo, an agonist producing comparable vasoconstriction to $\text{Ins}(1,4,5)\text{P}_3$ stimulator, we believe the LR-mediated activation of ADP-ribosylcyclase demonstrated in the present study is mainly attributed to this type of agonists. This LR-signaling mechanism may not be used by other Ca^{2+} regulatory pathways.

To explore the mechanism by which Oxo induces the formation of LR clusters with CD38 in CAMs, we tested a hypothesis that ASMase or ceramide plays a critical role in Oxo-induced LR clustering and thereby contributes to corresponding functional changes in CAMs or coronary arterial smooth muscle. There is considerable evidence that rapid activation and translocation of ASMase into cell membrane trigger or facilitate the formation of LR clusters in response to different stimuli (22). Recent studies in our laboratory have shown that lysosome-associated vesicle transportation or trafficking of ASMase from intracellular compartments to cell membrane is a prerequisite for ASMase activation in the process of LR clustering in endothelial cells (18). This ASMase translocated into cell membrane hydrolyzes SM to produce ceramide and leads to the formation of ceramide-enriched macrodomains or LR platforms, which cluster or recruit some receptors or signaling molecules (22). The present study provided several lines of evidence that this translocated ASMase and consequently produced ceramide are present in LR clusters with CD38 in CAMs and that ceramide production from ASMase importantly contributes to the formation and function of LR clusters with CD38. First, under stimulation of Oxo, ASMase and ceramide were found to be aggregated in LR clusters with CD38, as shown by the colocalization of GM_1 labeled by Alexa-CTX and ASMase, and ceramide labeled by Texas red-conjugated anti-ASMase antibody and Cy3-conjugated anti-ceramide antibody, respectively. Second, by membrane floatation, ASMase was found to be enriched in LR fractions and ASMase activity significantly increased in these fractions. The ASMase inhibitor, Des, could block these effects, but LR disruptors did not have obvious effects on Oxo-induced ASMase activation. These results suggest that ASMase enrichment and activation are involved in Oxo-induced LR clustering, and even ASMase activation precedes the LR clustering because the LR disruptors could not block the increased ASMase activity stimulated by Oxo. Third, a biochemical analysis demonstrated that ASMase inhibition by Des significantly blocked ADP-ribosylcyclase activity of CD38 in CAMs, indicating that ASMase importantly contributes to CD38 activation to produce cADPR. Fourth, functional studies by the measuring intracellular Ca^{2+} level in CAMs and the vasoconstrictor response of coronary arteries to Oxo provided evidence that ASMase inhibition attenuated the effect of Oxo-induced Ca^{2+} activation and vasoconstriction in these arteries. All these results support the view that ASMase and its product ceramide pathway play a crucial role in Oxo-induced LR

clustering and consequently CD38 activation and that the formation of these ceramide-enriched lipid platforms importantly participate in the CD38-cADPR-mediated signaling upon activation of M_1 receptor in CAMs.

Oxo or some other agonists may produce Ca^{2+} release and consequent vasoconstriction through several pathways such as activation of plasma membrane Ca^{2+} channels and $\text{Ins}(1,4,5)\text{P}_3$ production and resulting intracellular Ca^{2+} release. However, these two pathways will be blocked by using a Ca^{2+} -free bath solution in our Ca^{2+} assay and vasoreactivity studies as a routine in such studies. Under this condition, Ca^{2+} influx is blocked and therefore its role in mediating Oxo action was minimized. In addition, it was reported that when cells are bathed in Ca^{2+} free solution, PLC failed to respond to any stimulus to produce $\text{Ins}(1,4,5)\text{P}_3$ (34). Therefore, there was only a minimal action of $\text{Ins}(1,4,5)\text{P}_3$ in such preparations. However, our results did not exclude the action of Ca^{2+} influx or $\text{Ins}(1,4,5)\text{P}_3$ in the action of Oxo or other agonists under other conditions.

There was a concern regarding alternative pathways for cADPR production. It has been demonstrated that a soluble protein, ADP-ribosyl cyclase and its membrane-bound homologous CD38 and CD157, are involved in the production of cADPR with the substrate NAD^+ by a cyclizing reaction (9, 23), which has been shown in a variety of cells and tissues such as sea urchin eggs, pancreatic acinar cells, human T lymphocytes, rat brain, and rat smooth muscle cells. Over the last 10 years, we have demonstrated that this cADPR-mediated Ca^{2+} signaling is present in cardiovascular tissues such as the myocardium, renal microvessel, and coronary arteries (10, 32, 38). We also demonstrated that ADP-ribosylcyclase activity is primarily derived from CD38 (a GPI-anchored protein) in coronary arterial smooth muscle. In addition, other studies reported that CD38 internalization is of importance in mediating cADPR production in cell cytosol (14, 47). Therefore, based on current understanding, the high level of ADP-ribosylcyclase activity to convert NAD^+ to cADPR may be associated with the internalization of a membrane-bound enzyme, although there may be some unidentified pathways. One such unidentified pathway was reported recently in myometrial cells, which possesses ADP-ribosylcyclase activity to produce cADPR and NAADP independent of CD38 and CD157 (28). In addition, CD38-mediated cADPR has been reported to be enhanced by protein kinase A and cAMP-regulated guanine nucleotide exchange factor II (20). It seems that different type of cells may use different enzymatic pathways to produce cADPR. This CD38-independent pathway for cADPR production has not yet been demonstrated in vascular smooth muscle cells. However, our results in the present studies did not exclude the role of this CD38-independent pathway in mediating vascular reactivity under other conditions or when these cells are stimulated by other agonists.

In summary, the present study demonstrated that Oxo stimulated LR clustering in CAMs and that a membrane signaling complex or platforms could be formed by LR clustering. This LR clustering or formation of signaling platforms importantly participates in Ca^{2+} transient response of CAMs to Oxo and corresponding coronary arterial constriction. The Oxo-induced formation of LR signaling platform with CD38 as a complex was dependent on the enrichment and activation of ASMase and consequent production of ceramide. Therefore, it is the

ceramide-enriched macrodomain or lipid platforms that mediate the action of Oxo in mediating CD38 translocation and activation, thereby producing cADPR to induce Ca²⁺ release from the SR of CAMs. This LR clustering and consequent formation of signaling platforms may represent an important mechanism that is implicated in CD38/cADPR-mediated signaling in coronary arterial smooth muscle in response to vasoactive agonists such as Oxo.

GRANTS

This study was supported by National Institutes of Health Grants HL-57244, HL-75316, and DK-54927.

REFERENCES

- An NH, Han MK, Um C, Park BH, Park BJ, Kim HK, Kim UH. Significance of ecto-cyclase activity of CD38 in insulin secretion of mouse pancreatic islet cells. *Biochem Biophys Res Commun* 282: 781–786, 2001.
- Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. *Biochim Biophys Acta* 1746: 284–294, 2005.
- Chen YF, Zhang AY, Zou AP, Campbell WB, Li PL. Protein methylation activates reconstituted ryanodine receptor-ca release channels from coronary artery myocytes. *J Vasc Res* 41: 229–240, 2004.
- Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, Malavasi F. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. *Blood* 109: 5390–5398, 2007.
- Fellner SK, Arendshorst WJ. Angiotensin II Ca²⁺ signaling in rat afferent arterioles: stimulation of cyclic ADP ribose and IP₃ pathways. *Am J Physiol Renal Physiol* 288: F785–F791, 2005.
- Fliegert R, Gasser A, Guse AH. Regulation of calcium signalling by adenine-based second messengers. *Biochem Soc Trans* 35: 109–114, 2007.
- Fritz N, Macrez N, Mironneau J, Jeyakumar LH, Fleischer S, Morel JL. Ryanodine receptor subtype 2 encodes Ca²⁺ oscillations activated by acetylcholine via the M₂ muscarinic receptor/cADP-ribose signalling pathway in duodenum myocytes. *J Cell Sci* 118: 2261–2270, 2005.
- Furne C, Corset V, Herincs Z, Cahuzac N, Hueber AO, Mehlen P. The dependence receptor DCC requires lipid raft localization for cell death signaling. *Proc Natl Acad Sci USA* 103: 4128–4133, 2006.
- Gallione A. Cyclic ADP-ribose: a new way to control calcium. *Science* 259: 325–326, 1993.
- Ge ZD, Li PL, Chen YF, Gross GJ, Zou AP. Myocardial ischemia and reperfusion reduce the levels of cyclic ADP-ribose in rat myocardium. *Basic Res Cardiol* 97: 312–319, 2002.
- Ge ZD, Zhang DX, Chen YF, Yi FX, Zou AP, Campbell WB, Li PL. Cyclic ADP-ribose contributes to contraction and Ca²⁺ release by M₁ muscarinic receptor activation in coronary arterial smooth muscle. *J Vasc Res* 40: 28–36, 2003.
- Gupta N, DeFranco AL. Visualizing lipid raft dynamics and early signaling events during antigen receptor-mediated B-lymphocyte activation. *Mol Biol Cell* 14: 432–444, 2003.
- Guse AH, da Silva CP, Berg I, Skapenko AL, Weber K, Heyer P, Hohenegger M, Ashamu GA, Schulze-Koops H, Potter BV, Mayr GW. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. *Nature* 398: 70–73, 1999.
- Han MK, Kim SJ, Park YR, Shin YM, Park HJ, Park KJ, Park KH, Kim HK, Jang SI, An NH, Kim UH. Antidiabetic effect of a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, through CD38 dimerization and internalization. *J Biol Chem* 277: 5315–5321, 2002.
- Herincs Z, Corset V, Cahuzac N, Furne C, Castellani V, Hueber AO, Mehlen P. DCC association with lipid rafts is required for netrin-1-mediated axon guidance. *J Cell Sci* 118: 1687–1692, 2005.
- Horejsi V. The roles of membrane microdomains (rafts) in T cell activation. *Immunol Rev* 191: 148–164, 2003.
- Hunter I, Nixon GF. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipid rafts are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. *J Biol Chem* 281: 34705–34715, 2006.
- Jin S, Yi F, Li PL. Contribution of lysosomal vesicles to the formation of lipid raft redox signaling platforms in endothelial cells. *Antioxid Redox Signal* 9: 1417–1426, 2007.
- Jude JA, Wylam ME, Walseth TF, Kannan MS. Calcium signaling in airway smooth muscle. *Proc Am Thorac Soc* 5: 15–22, 2008.
- Kim BJ, Park KH, Yim CY, Takasawa S, Okamoto H, Im MJ, Kim UH. Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca²⁺ signal that is essential for insulin secretion in mouse pancreatic islets. *Diabetes* 57: 868–878, 2008.
- Kip SN, Smelter M, Iyanoye A, Chini EN, Prakash YS, Pabelick CM, Sieck GC. Agonist-induced cyclic ADP ribose production in airway smooth muscle. *Arch Biochem Biophys* 452: 102–107, 2006.
- Lacour S, Hammann A, Graziade S, Lagadic-Gossman D, Athias A, Sergent O, Laurent G, Gambert P, Solary E, Dimanche-Boitrel MT. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. *Cancer Res* 64: 3593–3598, 2004.
- Lee HC. Mechanisms of calcium signaling by cyclic ADP-ribose and NAADP. *Physiol Rev* 77: 1133–1164, 1997.
- Liu YT, Song L, Templeton DM. Heparin suppresses lipid raft-mediated signaling and ligand-independent EGF receptor activation. *J Cell Physiol* 211: 205–212, 2007.
- Munoz P, Navarro MD, Pavon EJ, Salmeron J, Malavasi F, Sancho J, Zubiaur M. CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor. *J Biol Chem* 278: 50791–50802, 2003.
- Noda M, Yasuda S, Okada M, Higashida H, Shimada A, Iwata N, Ozaki N, Nishikawa K, Shirasawa S, Uchida M, Aoki S, Wada K. Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. *J Neurochem* 84: 222–232, 2003.
- Shao D, Segal AW, Dekker LV. Lipid rafts determine efficiency of NADPH oxidase activation in neutrophils. *FEBS Lett* 550: 101–106, 2003.
- Soares S, Thompson M, White T, Isbell A, Yamasaki M, Prakash Y, Lund FE, Gallione A, Chini EN. NAADP as a second messenger: neither CD38 nor base-exchange reaction are necessary for in vivo generation of NAADP in myometrial cells. *Am J Physiol Cell Physiol* 292: C227–C239, 2007.
- Solomon JC, Sharma K, Wei LX, Fujita T, Shi YF. A novel role for sphingolipid intermediates in activation-induced cell death in T cells. *Cell Death Differ* 10: 193–202, 2003.
- Sprenger RR, Fontijn RD, van Marle J, Pannekoek H, Horrevoets AJ. Spatial segregation of transport and signalling functions between human endothelial caveolae and lipid raft proteomes. *Biochem J* 400: 401–410, 2006.
- Sturmeijer RG, O'Toole PJ, Leese HJ. Fluorescence resonance energy transfer analysis of mitochondrial:lipid association in the porcine oocyte. *Reproduction* 132: 829–837, 2006.
- Teggatz EG, Zhang G, Zhang AY, Yi F, Li N, Zou AP, Li PL. Role of cyclic ADP-ribose in Ca²⁺-induced Ca²⁺ release and vasoconstriction in small renal arteries. *Microvasc Res* 70: 65–75, 2005.
- Testai FD, Landek MA, Dawson G. Regulation of sphingomyelinases in cells of the oligodendrocyte lineage. *J Neurosci Res* 75: 66–74, 2004.
- Thore S, Dyachok O, Gylfe E, Tengholm A. Feedback activation of phospholipase C via intracellular mobilization and store-operated influx of Ca²⁺ in insulin-secreting beta-cells. *J Cell Sci* 118: 4463–4471, 2005.
- Trubiani O, Guarnieri S, Orciani M, Salvolini E, Di Primio R. Sphingolipid microdomains mediate CD38 internalization: topography of the endocytosis. *Int J Immunopathol Pharmacol* 17: 293–300, 2004.
- Van Munster EB, Kremers GJ, Adjobo-Hermans MJ, Gadella TW Jr. Fluorescence resonance energy transfer (FRET) measurement by gradual acceptor photobleaching. *J Microsc* 218: 253–262, 2005.
- Young GS, Jacobson EL, Kirkland JB. Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD⁺ metabolite cADPR. *J Nutr* 137: 1050–1057, 2007.
- Zhang AY, Li PL. Vascular physiology of a Ca²⁺ mobilizing second messenger-cyclic ADP-ribose. *J Cell Mol Med* 10: 407–422, 2006.
- Zhang AY, Yi F, Jin S, Xia M, Chen QZ, Gulbins E, Li PL. Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. *Antioxid Redox Signal* 9: 817–828, 2007.
- Zhang AY, Yi F, Teggatz EG, Zou AP, Li PL. Enhanced production and action of cyclic ADP-ribose during oxidative stress in

- small bovine coronary arterial smooth muscle. *Microvasc Res* 67: 159–167, 2004.
41. **Zhang AY, Yi F, Zhang G, Gulbins E, Li PL.** Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. *Hypertension* 47: 74–80, 2006.
 42. **Zhang DX, Harrison MD, Li PL.** Calcium-induced calcium release and cyclic ADP-ribose-mediated signaling in the myocytes from small coronary arteries. *Microvasc Res* 64: 339–348, 2002.
 43. **Zhang F, Jin S, Yi F, Xia M, Dewey WL, Li PL.** Local production of O_2^- by NAD(P)H oxidase in the sarcoplasmic reticulum of coronary arterial myocytes: cADPR-mediated Ca^{2+} regulation. *Cell Signal* 20: 637–644, 2008.
 44. **Zhang F, Zhang G, Zhang AY, Koeberl MJ, Wallander E, Li PL.** Production of NAADP and its role in Ca^{2+} mobilization associated with lysosomes in coronary arterial myocytes. *Am J Physiol Heart Circ Physiol* 291: H274–H282, 2006.
 45. **Zhang G, Zhang F, Muh R, Yi F, Chalupsky K, Cai H, Li PL.** Autocrine/paracrine pattern of superoxide production through NAD(P)H oxidase in coronary arterial myocytes. *Am J Physiol Heart Circ Physiol* 292: H483–H495, 2007.
 46. **Zilber MT, Setterblad N, Vasselon T, Doliger C, Charron D, Mooney N, Gelin C.** MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. *Blood* 106: 3074–3081, 2005.
 47. **Zocchi E, Usai C, Guida L, Franco L, Bruzzone S, Passalacqua M, De Flora A.** Ligand-induced internalization of CD38 results in intracellular Ca^{2+} mobilization: role of NAD⁺ transport across cell membranes. *FASEB J* 13: 273–283, 1999.
 48. **Zubiaur M, Fernandez O, Ferrero E, Salmeron J, Malissen B, Malavasi F, Sancho J.** CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. *J Biol Chem* 277: 13–22, 2002.



AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

1

AQ1— Please print out and read the PDF proof, answer all queries, and make corrections in the margins. Please do not manipulate the on-screen text with Adobe TouchUp Text Tool. Return the corrected PDF proof to AJP: Heart & Circulatory Physiology by overnight/express carrier within 48 hours, and send a fax copy in addition (FAX is 301-634-7243). Retain one copy of the corrected PDF for your records. Return the reprint order form to the printer to the address listed on the PDF instructions.

AQ5— Please verify accuracy of your e-mail address in the address for correspondence, or delete e-mail address if you do not want it included. (note: this material is listed as a footnote at bottom of left column of text, on the first page).

AQ2— Please note that the author list in the abstract line represents the form in which these names will appear in many online databases, such as the NCBI/NIH/NLM PubMed database. Check this carefully, and be sure there are no misrepresentations. Please make a note on the proof if any corrections are needed.

AQ3— Please note revised sentence [note: μM (micromolar) was changed to μm (micrometer)]:
“The intramural coronary arteries ($\leq 300 \mu\text{m}$ in diameter) were dissected from fresh cow hearts and assembled between two glass tips.” Was your meaning retained? If not, please fix on proof.

AQ4— You state the following: “...#P > 0.05 vs. control . . .” Please confirm that “greater than” and not “less than” was indeed meant here. If not, please fix on proof.
